|
USA-WI-MENASHA Azienda Directories
|
Azienda News:
- SMART-CHOICE 3: Clopidogrel Shows Benefit Over Aspirin Monotherapy . . .
Choi H, Park H, Lee JY, et al Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial Lancet Published online March 30, 2025 Doi: 10 1016 S0140-6736(25)00449-0
- Efficacy and safety of clopidogrel versus aspirin monotherapy in . . .
In this multicentre, randomised, open-label trial, patients aged 19 years or older at high risk of recurrent ischaemic events (previous myocardial infarction at any time before enrolment, medication-treated diabetes, or complex coronary lesions) who completed a standard duration of DAPT after PCI were randomly assigned (1:1) to receive clopidogrel (75 mg once a day) or aspirin (100 mg once a
- Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on . . .
Design, Setting, and Participants The SMART-CHOICE trial was an open-label, noninferiority, randomized study that was conducted in 33 hospitals in Korea and included 2993 patients undergoing PCI with drug-eluting stents Enrollment began March 18, 2014, and follow-up was completed July 19, 2018
- SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin . . .
The SMART-CHOICE 3 clinical trial was designed to assess whether clopidogrel monotherapy is superior to aspirin in terms of efficacy and safety in high risk patients after PCI This was a randomized, open, multicenter study carried out in 26 centers across South Korea between August 2020 and July 2023 After mean 17 5 month DAPT (RIC: 12 6–36
- Background (I) - clinicaltrialresults. org
SMART-CHOICE 3 (ClinicalTrials gov, NCT04418479) An investigator-initiated, randomized, open-label, multicenter trial at 26 sites in South Korea The SMART-CHOICE 3 trial was the first to demonstrate the benefits of clopidogrel monotherapy compared with aspirin monotherapy on a composite of hard endpoints in patients at a high risk of
- Clopidogrel Versus Aspirin Monotherapy in High-Risk Patients after . . .
Clopidogrel Versus Aspirin Monotherapy in High-Risk Patients after Percutaneous Coronary Intervention (SMART-CHOICE 3): A Randomised, Open-Label, Multicentre Trial 23 Pages Posted: 14 Feb 2025 See all articles by Ki Hong Choi
- ACC 25: The SMART-CHOICE 3 Trial | Radcliffe Cardiology
The SMART-CHOICE 3 trial was an investigator-initiated, prospective, randomised, open-label, multicentre trial that was conducted in 26 sites in South Korea We enrolled patients with high risk of recurrent ischemic events, in other words, prior MI, medication treated diabetes or complex PCI
- Clopidogrel Better Than Aspirin Long-Term After PCI - Medscape
SMART-CHOICE 3 Trial SMART-CHOICE 3 assessed 5500 patients who underwent PCI in South Korea and were at high risk for a future ischemic event because of a history of heart attack, medication
- Efficacy and safety of clopidogrel versus aspirin monotherapy in . . .
knowledge, SMART-CHOICE 3 is the first trial to show a benefit of clopidogrel monotherapy over aspirin monotherapy on a hard ischaemic endpoint after PCI There was no difference in the incidence of BARC type 2, 3, or 5 bleeding between the clopidogrel and aspirin groups The risk of upper gastrointestinal
- assets. radcliffecardiology. com
The SMART-CHOICE 3 trial was an investigator-initiated, prospective, randomised, open-label, multicentre trial that was conducted in 26 sites in South Korea We enrolled patients with high risk of recurrent ischemic events, in other words, prior MI, medication treated diabetes or complex PCI
|
|